Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
Date:10/1/2010

s that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Haemonetics Corporation (NYSE: ... Chief Operating Officer, will present at the JMP Securities ... on June 23 rd , 2015 at 11:30am ... Mr. Davies, presentation live via webcast at: http://wsw.com/webcast/jmp27/hae ... HAE ) is a global healthcare company dedicated ...
(Date:5/29/2015)...  Eli Lilly and Company (NYSE: LLY ) ... they have entered into a clinical trial collaboration to ... anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ... medicine. The planned study will assess the combination as ... The Phase I study is expected to establish ...
(Date:5/29/2015)... MALVERN, Pa. , May 29, 2015 /PRNewswire-USNewswire/ ... major focus of the Association for the Advancement ... 1995. With support from AAWC,s corporate ... Educational Portal on the AAWC website ... on a wound care pathway with links to ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14The Association for the Advancement of Wound Care Educates the Public 2
... MINNEAPOLIS, Sept. 27, 2011 Visiting Nurse Services ... largest home health agencies, announces that it has ... provide advanced home telehealth technology to patients with ...  Cardiocom®, Experts in Telehealth(SM), is a world class ...
... NEW YORK, Sept. 27, 2011 NeoStem, Inc. (NYSE Amex: ... biopharmaceutical company with a focus on cell-based therapeutic development, today ... presentation at the 6th Annual JMP Securities Healthcare Conference. Dr. ... Andrew L. Pecora, Chief Medical Officer of NeoStem, will now ...
Cached Medicine Technology:Visiting Nurse Services of Connecticut Selects Cardiocom® As Its New Telehealth Vendor 2NeoStem Announces Change in Presentation Time for JMP Securities Conference 2NeoStem Announces Change in Presentation Time for JMP Securities Conference 3
(Date:5/29/2015)... 29, 2015 OncLive proudly announces the ... medical pioneers recognized by a panel of eminent oncologists ... cancer treatment. Honorees will be introduced and celebrated TONIGHT ... Ceremony, held 8:30-11:00 p.m. CDT at The Chicago Illuminating ... are being recognized for groundbreaking accomplishments, in fields including ...
(Date:5/29/2015)... The Global Allopurinol Industry Report ... the current state of the Allopurinol industry.With 147 ... on the state of the industry and is ... companies and individuals interested in the market. The ... including definitions, classifications, applications and industry chain structure. ...
(Date:5/29/2015)... 29, 2015 Healthpointe’s electromyography and ... the Los Angeles County clinics including its newest ... now being offered at all Healthpointe locations throughout ... San Bernardino County. , As the muscles ... send electrical impulses throughout the body and dictate ...
(Date:5/29/2015)... is excited to announce that they are now offering ... Orange County. The Supartz Therapy is a cost-effective, minimally ... patients with osteoarthritis, and will be administered by renowned ... Healthpointe. Supartz is an injection of made from highly ... natural substance found in joint cartilage. Also known as ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 For the third ... to bring the Denver youth ultimate community an opportunity to ... and individual improvement. The mission of the USAU Nike Ultimate ... and girls to improve, build character, and make lifelong friends. ... boys and girls of all skill and ability levels, ages ...
Breaking Medicine News(10 mins):Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4Health News:Allopurinol Industry (Global, China) 2015 Research Analysis and 2020 Forecasts 2Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2Health News:Healthpointe is Now Offering Supartz Joint Fluid Therapy at their Anaheim Clinic and La Mirada Clinic. 2Health News:US Sports Camps, Nike Sports Camps, and USA Ultimate Host Third Summer of Ultimate Camp in Denver 2
... According to a survey done by the U.S. government it was ... among the America's elderly population//. It is said that adults aged ... estimated that the number of people addicted to drug would double ... generation is addicted to drugs due to problems such as pain, ...
... Drug addiction is becoming a significant public health probelm ... that the number of individuals with drug addiction// problems ... of 2020. ,Nearly 2.5 million Americans have ... 1999. The increasing inclination of elders to take drugs ...
... collaborate to prove through clinical trials the efficacy of ... known to cure but for which there is no ... collaboration has been approved by the board members and ... to the government for seeking funding," said Ranjit Roy ...
... has confirmed five more bird flu related deaths in Indonesia, ... team has further been sent to the northern Sumatra region, ... same family) had lived. The fifth victim was a 38-year-old ... and meat. ,,It is further suspected that eight ...
... helps to protect the lungs of premature infants from ... McMaster University researchers have reported// an early finding in ... caffeine therapy for the treatment of apnoea of prematurity. ... preterm infants, because the lungs are underdeveloped and the ...
... will not be allowed to make tall claims on their ... EU lawmakers have clamped down on misleading claims or health ... to set a common standard for vitamins, minerals and food ... manufacturers who are not able to justify their claims will ...
Cached Medicine News:Health News:Indian And Chinese Doctors Join Together To Prove The Efficacy Of Herbal Drugs 2Health News:Indian And Chinese Doctors Join Together To Prove The Efficacy Of Herbal Drugs 3Health News:Caffeine Therapy May Help Protect Lungs Of Premature Babies 2
Straight shafts with 4 mm platform. Wide serrated handle with dull finish. Platform straight....
Curved shafts with 2 mm angled platform. Wide serrated handle with dull finish....
Straight shafts with micro tips and sandblast finish. Insulated smooth handle....
Double-ended. 12 mm bayonet shaped blade. 10 mm curved blade....
Medicine Products: